EMA Authorised: Lynparza (olaparib) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Lynparza (olaparib) for multiple cancers in the European Union. Indications include ovarian cancer, breast cancer, pancreatic cancer, and cas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Breast Neoplasms;Pancreatic Neoplasms;Prostatic Neoplasms, Castration-Resistant. MAH: AstraZeneca AB. Decision date: 12/02/2026